Loading clinical trials...

Primary Tumor Sidedness Associated With Clinical Characteristic and Postoperative Outcomes in Colon Cancer: a Propensity Score Matching Study | Clinical Trials | Clareo Health

COMPLETED

Primary Tumor Sidedness Associated With Clinical Characteristic and Postoperative Outcomes in Colon Cancer: a Propensity Score Matching Study

NCT06184555•Chang Gung Memorial Hospital

View on ClinicalTrials.gov

Summary

Background: Recent investigations have suggested that sidedness is associated with the prognosis of colon cancer patients. The role of sidedness in surgical outcome is unclear. The aim of this study was to investigate the different clinical characteristics and associated postoperative outcomes of sidedness in colon cancer. Materials and methods: This is a retrospective study using the multi-institutional, nationally validated database of the American College of Surgeons-National Surgical Quality Improvement Program (ACS-NSQIP) from 2009 to 2013. Sidedness groups including right sided and left sided colon cancer were created according to the associated diagnosis and procedure codes. Postoperative mortality, morbidity, overall complication, and length of total hospital stay were analyzed after using a propensity score matching method.

Eligibility

Age

All ages

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•colon cancer S/P colectomy

Exclusion Criteria

•\-

Key Dates

Start Date

January 1, 2009

Primary Completion Date

December 31, 2013

Completion Date

December 31, 2013

Last Updated

December 28, 2023

Enrollment

24,436

ACTUAL participants

Conditions

Colorectal Cancer

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

NCT04704661

Advanced Breast CarcinomaAdvanced Colon Carcinoma+38 more

View study

RECRUITINGPHASE1

Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer

NCT06696768

Metastatic Colorectal AdenocarcinomaStage III Colorectal Cancer AJCC v8+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 28, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Primary Tumor Sidedness Associated With Clinical Characteristic and Postoperative Outcomes in Colon Cancer: a Propensity Score Matching Study

Inclusion Criteria

Exclusion Criteria

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease